{"organizations": [], "uuid": "f1e6febe6f35dab2d992ebc014e8543378a96adc", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-rigel-to-provide-business-review-a/brief-rigel-to-provide-business-review-and-updated-phase-2-results-for-fostamatinib-idUSFWN1OZ0MQ", "country": "US", "domain_rank": 408, "title": "BRIEF-Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-04T14:35:00.000+02:00", "replies_count": 0, "uuid": "f1e6febe6f35dab2d992ebc014e8543378a96adc"}, "author": "", "url": "https://www.reuters.com/article/brief-rigel-to-provide-business-review-a/brief-rigel-to-provide-business-review-and-updated-phase-2-results-for-fostamatinib-idUSFWN1OZ0MQ", "ord_in_thread": 0, "title": "BRIEF-Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "provide business review", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "rigel pharmaceuticals inc", "sentiment": "none"}, {"name": "fostamatinib reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "rigel pharmaceuticals inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 36 PM / Updated 8 minutes ago BRIEF-Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib Reuters Staff 1 Min Read \nJan 4 (Reuters) - Rigel Pharmaceuticals Inc: \n* RIGEL PHARMACEUTICALS - ‍FDA HAS CONFIRMED IT DOES NOT PLAN TO CONVENE ONCOLOGY DRUGS ADVISORY COMMITTEE MEETING TO DISCUSS NDA FOR FOSTAMATINIB​ \n* RIGEL PHARMACEUTICALS INC - ACTION DATE FOR FDA TO COMPLETE ITS REVIEW FOR FOSTAMATINIB IS APRIL 17, 2018 UNDER PDUFA Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-04T14:35:00.000+02:00", "crawled": "2018-01-04T14:47:45.024+02:00", "highlightTitle": ""}